PREVIEW

India’s Cheap Weight Loss Drugs Could Transform Global Obesity Fight. India could be on the verge of a major shift in the fight against obesity. The patent on semaglutide, the key ingredient in drugs like Ozempic and Wegovy , is set to expire, opening the door to cheaper alternatives. This means Indian pharmaceutical companies can produce generic versions, driving down prices and expanding access. Experts say costs could fall by more than half, making treatment far more affordable for millions. India’s competitive drug industry is expected to move quickly, with dozens of new versions likely to launch within months. Major firms are already preparing their own generics. Right now, these treatments remain expensive, putting them out of reach for many. But lower prices could change that — not just in India, but globally. A shift that could reshape the fight against obesity.
Instructions: THIS VIDEO MUST NOT BE EDITED FOR LENGTH TO COMBINE WITH OTHER CONTENT